Medtronic plc is looking to increase market share in pain stimulation with its differential target multiplexed (DTM) therapy, a recharge-free device and its next big disrupter, evoked compound action potential (ECAP). The company is currently developing a closed-loop SCS system for chronic pain following failed back surgery based on ECAP and DTM algorithms.
Keeping you up to date on recent developments in diagnostics, including: Increasing COVID-19 detection through secondary distribution of self-tests; COVID-19 and breath analysis; Saving lives from colorectal cancer; New classification scheme for glioblastomas.
Haemonetics Corp. said Wednesday that it will acquire Cardiva Medical Inc., a privately held manufacturer of blood closure systems, for up to $510 million. The all-cash deal expands Haemonetics’ hospital portfolio with two catheter-based devices used to shut off access sites following minimally invasive cardiology and electrophysiology (EP) procedures.
Thermo Fisher Scientific Inc. has inked a definitive agreement to acquire Mesa Biotech Inc., a privately held molecular diagnostics company with a point-of-care (POC) platform, for approximately $450 million in cash. The scientific instruments and testing giant said it will pay an additional $100 million in cash upon the completion of certain milestones. The planned acquisition will expand Thermo Fisher’s franchise of diagnostic test options with a novel platform that enables nucleic acid polymerase chain reaction (PCR) testing at the point of care.
Abbott Laboratories plans to launch its Neurosphere Mypath digital health app in the coming weeks, the latest addition to its Neurosphere Digital Care connected health management platform. The new app will enable chronic pain patients trying out Abbott neuromodulation therapies to track and report their pain relief.
Liquid biopsy startup Delfi Diagnostics Inc. scooped up $100 million in a series A round led by Orbimed Advisors LLC. The company will use the funds to grow its team of cancer researchers and machine learning experts and to validate its next-generation blood-based testing technology in prospective clinical trials. Existing investors Menlo Ventures, Samsara Biocapital, Illumina Ventures, Av8 Ventures also participated in the round, along with new investors Foresite Capital, Northpond Ventures, Cowen Healthcare Investments and Rock Springs Capital.
Keeping you up to date on recent developments in diagnostics, including: Improving diagnosis of brain diseases; Predicting survival of COVID-19 patients; New causal gene for chronic kidney disease.
Glaukos Corp. reported 12-month results from the pivotal IDE trial of its Istent Infinite trabecular micro-bypass system, showing substantial reduction in mean diurnal intraocular pressure (IOP) in patients with open-angle glaucoma uncontrolled by prior surgery or medication. The company is targeting U.S. FDA approval of the device for standalone moderate-to-severe glaucoma in late 2021.
Steris plc has agreed to buy Cantel Medical Corp. for approximately $3.6 billion, in a cash and stock transaction that unites two key players in the infection prevention space. The combined company offers a number of synergies. Cantel’s medical portfolio is expected to bolster and expand Steris’ endoscopy offerings, with a full-suite of high-level disinfection consumables, capital equipment and services plus single-use accessories.
Neuros Medical Inc., a company developing neuromodulation technology to treat intractable post-amputation pain, has raised $38.5 million in a series BB financing. The funds will be used to complete enrollment in its pivotal QUEST clinical trial and to submit a premarket approval application to the U.S. FDA. New investors Amzak Health and Sectoral Asset Management co-led the round.
